vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
Ecovyst Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.3倍（$199.4M vs $152.6M），Ecovyst Inc.同比增速更快（34.0% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $22.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 18.7%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
CPRX vs ECVT — 直观对比
营收规模更大
ECVT
是对方的1.3倍
$152.6M
营收增速更快
ECVT
高出26.4%
7.6%
自由现金流更多
CPRX
多$21.9M
$22.9M
两年增速更快
CPRX
近两年复合增速
18.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $199.4M |
| 净利润 | $52.7M | — |
| 毛利率 | 82.9% | 23.4% |
| 营业利润率 | 40.5% | 10.9% |
| 净利率 | 34.5% | — |
| 营收同比 | 7.6% | 34.0% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXECVT
| Q4 25 | $152.6M | $199.4M | ||
| Q3 25 | $148.4M | $204.9M | ||
| Q2 25 | $146.6M | $176.1M | ||
| Q1 25 | $141.4M | $143.1M | ||
| Q4 24 | $141.8M | $148.9M | ||
| Q3 24 | $128.7M | $153.9M | ||
| Q2 24 | $122.7M | $154.0M | ||
| Q1 24 | $98.5M | $141.6M |
净利润CPRXECVT
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $-79.3M | ||
| Q2 25 | $52.1M | $6.0M | ||
| Q1 25 | $56.7M | $-3.6M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $14.3M | ||
| Q2 24 | $40.8M | $8.3M | ||
| Q1 24 | $23.3M | $1.2M |
毛利率CPRXECVT
| Q4 25 | 82.9% | 23.4% | ||
| Q3 25 | 84.7% | 25.4% | ||
| Q2 25 | 85.9% | 22.8% | ||
| Q1 25 | 87.3% | 13.3% | ||
| Q4 24 | 84.7% | 28.9% | ||
| Q3 24 | 85.0% | 29.3% | ||
| Q2 24 | 87.4% | 27.3% | ||
| Q1 24 | 87.3% | 23.5% |
营业利润率CPRXECVT
| Q4 25 | 40.5% | 10.9% | ||
| Q3 25 | 44.7% | 13.8% | ||
| Q2 25 | 45.2% | 9.0% | ||
| Q1 25 | 44.8% | -0.7% | ||
| Q4 24 | 44.3% | 15.1% | ||
| Q3 24 | 39.6% | 17.9% | ||
| Q2 24 | 44.2% | 14.1% | ||
| Q1 24 | 27.5% | 9.5% |
净利率CPRXECVT
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | -38.7% | ||
| Q2 25 | 35.6% | 3.4% | ||
| Q1 25 | 40.1% | -2.5% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 9.3% | ||
| Q2 24 | 33.2% | 5.4% | ||
| Q1 24 | 23.6% | 0.9% |
每股收益（稀释后）CPRXECVT
| Q4 25 | $0.40 | $0.06 | ||
| Q3 25 | $0.42 | $-0.69 | ||
| Q2 25 | $0.41 | $0.05 | ||
| Q1 25 | $0.45 | $-0.03 | ||
| Q4 24 | $0.44 | $-0.26 | ||
| Q3 24 | $0.35 | $0.12 | ||
| Q2 24 | $0.33 | $0.07 | ||
| Q1 24 | $0.19 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $197.2M |
| 总债务越低越好 | — | $392.6M |
| 股东权益账面价值 | $954.3M | $603.4M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资CPRXECVT
| Q4 25 | $709.2M | $197.2M | ||
| Q3 25 | $689.9M | $82.0M | ||
| Q2 25 | $652.8M | $69.6M | ||
| Q1 25 | $580.7M | $127.5M | ||
| Q4 24 | $517.6M | $131.4M | ||
| Q3 24 | $442.3M | $123.5M | ||
| Q2 24 | $375.7M | $83.3M | ||
| Q1 24 | $310.4M | $103.1M |
总债务CPRXECVT
| Q4 25 | — | $392.6M | ||
| Q3 25 | — | $854.8M | ||
| Q2 25 | — | $856.6M | ||
| Q1 25 | — | $859.0M | ||
| Q4 24 | — | $860.8M | ||
| Q3 24 | — | $862.7M | ||
| Q2 24 | — | $862.4M | ||
| Q1 24 | — | $866.2M |
股东权益CPRXECVT
| Q4 25 | $954.3M | $603.4M | ||
| Q3 25 | $920.2M | $607.9M | ||
| Q2 25 | $856.0M | $692.4M | ||
| Q1 25 | $794.3M | $698.7M | ||
| Q4 24 | $727.6M | $700.5M | ||
| Q3 24 | $660.9M | $729.4M | ||
| Q2 24 | $608.7M | $717.3M | ||
| Q1 24 | $561.4M | $711.4M |
总资产CPRXECVT
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.8B | ||
| Q1 25 | $908.9M | $1.8B | ||
| Q4 24 | $851.4M | $1.8B | ||
| Q3 24 | $772.0M | $1.8B | ||
| Q2 24 | $706.4M | $1.8B | ||
| Q1 24 | $646.7M | $1.8B |
负债/权益比CPRXECVT
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $41.8M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $22.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 11.5% |
| 资本支出强度资本支出/营收 | 0.0% | 9.4% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $69.9M |
8季度趋势，按日历期对齐
经营现金流CPRXECVT
| Q4 25 | $44.9M | $41.8M | ||
| Q3 25 | $32.4M | $55.3M | ||
| Q2 25 | $71.3M | $33.0M | ||
| Q1 25 | $60.0M | $10.3M | ||
| Q4 24 | $70.9M | $43.5M | ||
| Q3 24 | $72.9M | $59.9M | ||
| Q2 24 | $64.1M | $10.0M | ||
| Q1 24 | $31.9M | $36.5M |
自由现金流CPRXECVT
| Q4 25 | $44.9M | $22.9M | ||
| Q3 25 | — | $53.2M | ||
| Q2 25 | $71.3M | $7.8M | ||
| Q1 25 | — | $-14.0M | ||
| Q4 24 | $70.8M | $30.9M | ||
| Q3 24 | $72.6M | $53.6M | ||
| Q2 24 | $64.1M | $-9.3M | ||
| Q1 24 | $31.7M | $19.1M |
自由现金流率CPRXECVT
| Q4 25 | 29.4% | 11.5% | ||
| Q3 25 | — | 26.0% | ||
| Q2 25 | 48.6% | 4.4% | ||
| Q1 25 | — | -9.8% | ||
| Q4 24 | 49.9% | 20.7% | ||
| Q3 24 | 56.4% | 34.9% | ||
| Q2 24 | 52.3% | -6.1% | ||
| Q1 24 | 32.2% | 13.5% |
资本支出强度CPRXECVT
| Q4 25 | 0.0% | 9.4% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 14.4% | ||
| Q1 25 | 0.0% | 16.9% | ||
| Q4 24 | 0.1% | 8.5% | ||
| Q3 24 | 0.2% | 4.1% | ||
| Q2 24 | 0.0% | 12.5% | ||
| Q1 24 | 0.2% | 12.3% |
现金转化率CPRXECVT
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | 5.52× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 4.21× | ||
| Q2 24 | 1.57× | 1.20× | ||
| Q1 24 | 1.37× | 29.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
